Ersodetug, a novel, fully human monoclonal antibody for the treatment of hyperinsulinism (HI), receives Breakthrough Therapy Designation and ...

Rezolute (RZLT) announced that the independent data monitoring committee reviewed safety and pharmacokinetics in eight infant patients in the ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.C79yHELW.js ...

Rezolute has a fifty-two week low of $0.98 and a fifty-two week high of $6.19. The firm has a market cap of $284.50 million, a price-to-earnings ratio of -3.87 and a beta of 1.10.

Open-label arm (infant participants < 1 year old) has been recently reviewed by a Data Monitoring Committee (DMC) and target drug concentrations were safely reached at tested doses DMC approved ...

Open-label arm (infant participants DMC approved enrollment of infants into the double-blind portion of the study sunRIZE enrollment completion expected in Q2 2025, subject to outcomes from upcoming ...

JMP Securities adjusted its financial outlook for Rezolute (NASDAQ:RZLT), increasing the price target to $9.00 from the previous $8.00, while keeping a Market Outperform rating on the stock. Currently ...

REDWOOD CITY, Calif. - Rezolute , Inc. (NASDAQ:RZLT), a biopharmaceutical company with a market capitalization of $303.62 million and impressive recent momentum (up 13.91% in the past week ...

Rezolute, Inc. announced that the Data Monitoring Committee (DMC) has reviewed the open-label arm of its Phase 3 sunRIZE study for the treatment of congenital hyperinsulinism with ersodetug in ...